Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
Status:
Unknown status
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor
sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis
complex or sporadic lymphangioleiomyomatosis.
Phase:
Phase 2
Details
Lead Sponsor:
Cardiff University
Collaborators:
Royal Sussex County Hospital St Georges Hospital Medical School The Tuberous Sclerosis Association University of Nottingham Wyeth is now a wholly owned subsidiary of Pfizer